Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies
<p>Abstract</p> <p>Background</p> <p>Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-like particles (VLPs) and they have been shown to protect against natural HPV16 and HPV18 infections and associated lesions. In addition, limited c...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-03-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | http://www.translational-medicine.com/content/8/1/28 |
| _version_ | 1818063079708033024 |
|---|---|
| author | Duarte-Forero Diego F Gaitan Julien Ribeiro Tatiana Fleury Maxime JJ Saussereau Emilie Combelas Nicolas Coursaget Pierre Touzé Antoine |
| author_facet | Duarte-Forero Diego F Gaitan Julien Ribeiro Tatiana Fleury Maxime JJ Saussereau Emilie Combelas Nicolas Coursaget Pierre Touzé Antoine |
| author_sort | Duarte-Forero Diego F |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-like particles (VLPs) and they have been shown to protect against natural HPV16 and HPV18 infections and associated lesions. In addition, limited cross-protection has been observed against closely related types. Immunization with L2 protein in animal models has been shown to provide cross-protection against distant papillomavirus types, suggesting that the L2 protein contains cross-neutralizing epitopes. However, vaccination with L2 protein or L2 peptides does not induce high titers of anti-L2 antibodies. In order to develop a vaccine with the potential to protect against other high-risk HPV types, we have produced HPV58 pseudovirions encoding the HPV31 L2 protein and compared their capacity to induce cross-neutralizing antibodies with that of HPV L1 and HPV L1/L2 VLPs.</p> <p>Methods</p> <p>The titers of neutralizing antibodies against HPV16, HPV18, HPV31 and HPV58 induced in Balb/c mice were compared after immunization with L2-containing vaccines.</p> <p>Results</p> <p>Low titers of cross-neutralizing antibodies were detected in mice when immunized with L1/L2 VLPs, and the highest levels of cross-neutralizing antibodies were observed in mice immunized with HPV 58 L1/L2 pseudovirions encoding the HPV 31 L2 protein.</p> <p>Conclusions</p> <p>The results obtained indicate that high levels of cross-neutralizing antibodies are only observed after immunization with pseudovirions encoding the L2 protein. HPV pseudovirions thus represent a possible new strategy for the generation of a broad-spectrum vaccine to protect against high-risk HPVs and associated neoplasia.</p> |
| first_indexed | 2024-12-10T14:14:24Z |
| format | Article |
| id | doaj.art-6b83155a7c7443df830230b83d3a2bc6 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-10T14:14:24Z |
| publishDate | 2010-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-6b83155a7c7443df830230b83d3a2bc62022-12-22T01:45:22ZengBMCJournal of Translational Medicine1479-58762010-03-01812810.1186/1479-5876-8-28Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodiesDuarte-Forero Diego FGaitan JulienRibeiro TatianaFleury Maxime JJSaussereau EmilieCombelas NicolasCoursaget PierreTouzé Antoine<p>Abstract</p> <p>Background</p> <p>Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-like particles (VLPs) and they have been shown to protect against natural HPV16 and HPV18 infections and associated lesions. In addition, limited cross-protection has been observed against closely related types. Immunization with L2 protein in animal models has been shown to provide cross-protection against distant papillomavirus types, suggesting that the L2 protein contains cross-neutralizing epitopes. However, vaccination with L2 protein or L2 peptides does not induce high titers of anti-L2 antibodies. In order to develop a vaccine with the potential to protect against other high-risk HPV types, we have produced HPV58 pseudovirions encoding the HPV31 L2 protein and compared their capacity to induce cross-neutralizing antibodies with that of HPV L1 and HPV L1/L2 VLPs.</p> <p>Methods</p> <p>The titers of neutralizing antibodies against HPV16, HPV18, HPV31 and HPV58 induced in Balb/c mice were compared after immunization with L2-containing vaccines.</p> <p>Results</p> <p>Low titers of cross-neutralizing antibodies were detected in mice when immunized with L1/L2 VLPs, and the highest levels of cross-neutralizing antibodies were observed in mice immunized with HPV 58 L1/L2 pseudovirions encoding the HPV 31 L2 protein.</p> <p>Conclusions</p> <p>The results obtained indicate that high levels of cross-neutralizing antibodies are only observed after immunization with pseudovirions encoding the L2 protein. HPV pseudovirions thus represent a possible new strategy for the generation of a broad-spectrum vaccine to protect against high-risk HPVs and associated neoplasia.</p>http://www.translational-medicine.com/content/8/1/28 |
| spellingShingle | Duarte-Forero Diego F Gaitan Julien Ribeiro Tatiana Fleury Maxime JJ Saussereau Emilie Combelas Nicolas Coursaget Pierre Touzé Antoine Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies Journal of Translational Medicine |
| title | Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies |
| title_full | Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies |
| title_fullStr | Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies |
| title_full_unstemmed | Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies |
| title_short | Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies |
| title_sort | papillomavirus pseudovirions packaged with the l2 gene induce cross neutralizing antibodies |
| url | http://www.translational-medicine.com/content/8/1/28 |
| work_keys_str_mv | AT duarteforerodiegof papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT gaitanjulien papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT ribeirotatiana papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT fleurymaximejj papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT saussereauemilie papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT combelasnicolas papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT coursagetpierre papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies AT touzeantoine papillomaviruspseudovirionspackagedwiththel2geneinducecrossneutralizingantibodies |